Patients in control group were treated with FOLFOXIRI. On the 1st day, 150–180 mg/m2 irinotecan (approval no. NMPN H20084572; Qilu Pharmaceutical Hainan Co., Ltd., Shandong, China) was intravenously injected for 90 min, and 200 mg/m2 calcium folinate (approval no. NMPN H20000584; Jiangsu Hengrui Medicine Co., Ltd., Jiangsu, China) was also intravenously injected for 2 h; then 400 mg/m2 5-fluorouracil (approval no. NMPN H31020593; Shanghai Xudong Haipu Pharmaceutical Co., Ltd., Shanghai, China) was intravenously injected, and then 2,400 mg/m2 5-fluorouracil was pumped into peripheral vein for 46 h. Patients in observation, based on the treatment in control group, received intravenous drip of 5 mg/kg bevacizumab (approval no. registration certificate no. S20120068; Roche Diagnostics, Indianapolis, IN, USA) for ≥1.5 h in the first, and for ≤1 h in the second time. Two groups of patients received the above treatment once every two weeks. After treatment, the curative effects on patients were dynamically evaluated, and the surgical resection could be scheduled when it was resectable. This study was approved by the Ethics Committee of The Second Affiliated Hospital of Zhengzhou University. Signed written informed consents were obtained from the patients and/or guardians.
Irinotecan
Manufactured by Qilu Pharmaceutical
Sourced in China
Irinotecan is a laboratory equipment used in the pharmaceutical industry. It is a topoisomerase I inhibitor, which means it interferes with the action of the enzyme topoisomerase I, which is involved in the replication and transcription of DNA. Irinotecan is commonly used in the development and testing of cancer treatments.
Automatically generated - may contain errors
2 protocols using irinotecan
1
FOLFOXIRI plus Bevacizumab for Colorectal Cancer
2
Evaluating Anticancer Efficacy of Deoxyshikonin
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
A total of 20 male BALB/c nude mice with body weights of 10–14 g, were purchased from Hunan SJA Laboratory Animal Limited Company and maintained in a specific pathogen-free environment. Animal experiments were approved by the Guangdong Medical University Institutional Animal Care and Use Committee. After 2 weeks, mice were injected with DLD-1 cells (1 × 107 cell in a volume of 0.2 mL) into the subcutaneous tissue of the right auxiliary region. The volume of the tumour was measured every other day by caliper and calculated by the following formula: (length × width × width)/2. When tumours reached a volume of 62.5 mm3, mice were divided randomly into the following four groups and given different drugs by intraperitoneal injection for a total of 13 days: control, DMSO (1% DMSO, every two days), deoxyshikonin (20 mg/kg in 1% DMSO, every two days), irinotecan (66.7 mg/kg, every four days, Qilu Pharmaceutical Co. Ltd, Hainan, China). On day 13, all mice were sacrificed. The tumours were segregated, measured and stored in liquid nitrogen for later use.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!